-
公开(公告)号:US20120184453A1
公开(公告)日:2012-07-19
申请号:US13348098
申请日:2012-01-11
申请人: Ting-Huei WANG , Yen-Peng LI , Pei-Fen KUO , Shih-Ya CHEN , Chia-Ju LIN , Jenq-Chang LEE , Angelina Huai-Lo LEE
发明人: Ting-Huei WANG , Yen-Peng LI , Pei-Fen KUO , Shih-Ya CHEN , Chia-Ju LIN , Jenq-Chang LEE , Angelina Huai-Lo LEE
CPC分类号: C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178 , G16B20/00
摘要: Methods for determining the likelihood of colorectal cancer (CRC) recurrence in a subject that involve measuring the expression level of two or more micro ribonucleic acids (miRNAs) in a biological sample comprising CRC tumor cells from said subject and using the normalized, measured expression levels to determine the likelihood of colorectal cancer recurrence for said subject. In the methods, the normalized expression levels of specific miRNAs are weighted by their contribution to CRC recurrence to calculate the likelihood of CRC recurrence. Kits for measuring the expression level of specific miRNAs that can be used in determining the likelihood of CRC recurrence are also provided.
摘要翻译: 用于确定受试者中包括测量包含来自所述受试者的CRC肿瘤细胞的生物样品中两种或更多种微核糖核酸(miRNA)的表达水平的表达水平的受试者中的结直肠癌(CRC)复发的可能性的方法,并使用归一化的测量的表达水平 以确定所述受试者的结肠直肠癌复发的可能性。 在方法中,特异性miRNA的归一化表达水平由其对CRC复发的贡献加权,以计算CRC复发的可能性。 还提供了用于测定可用于确定CRC复发可能性的特异性miRNA的表达水平的试剂盒。
-
公开(公告)号:US08465980B2
公开(公告)日:2013-06-18
申请号:US12694575
申请日:2010-01-27
申请人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
发明人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
CPC分类号: G01N33/6893 , G01N2333/4728 , G01N2333/52 , G01N2333/71 , G01N2333/8125 , G01N2800/347 , G01N2800/52 , G01N2800/56
摘要: Disclosed is use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
-
3.
公开(公告)号:US20110086371A1
公开(公告)日:2011-04-14
申请号:US12972936
申请日:2010-12-20
申请人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
发明人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
IPC分类号: G01N33/53 , C07K16/18 , G01N33/566
CPC分类号: G01N33/6893 , G01N2333/4728 , G01N2333/52 , G01N2333/71 , G01N2333/8125 , G01N2800/347 , G01N2800/52 , G01N2800/56
摘要: Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
摘要翻译: 使用尿液和血清生物标志物诊断糖尿病肾病,分期糖尿病肾病,监测糖尿病肾病进展,评估糖尿病肾病治疗效果。 这些生物标志物包括尿前体α-2-HS-糖蛋白,尿α-1抗胰蛋白酶,尿α-1酸糖蛋白,尿骨桥蛋白,血清骨桥蛋白,其片段及其组合。
-
4.
公开(公告)号:US20110079077A1
公开(公告)日:2011-04-07
申请号:US12969039
申请日:2010-12-15
申请人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
发明人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
IPC分类号: G01N1/10
CPC分类号: G01N33/6893 , G01N2333/4728 , G01N2333/52 , G01N2333/71 , G01N2333/8125 , G01N2800/347 , G01N2800/52 , G01N2800/56
摘要: Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
摘要翻译: 使用尿液和血清生物标志物诊断糖尿病肾病,分期糖尿病肾病,监测糖尿病肾病进展,评估糖尿病肾病治疗效果。 这些生物标志物包括尿前体α-2-HS-糖蛋白,尿α-1抗胰蛋白酶,尿α-1酸糖蛋白,尿骨桥蛋白,血清骨桥蛋白,其片段及其组合。
-
5.
公开(公告)号:US08476077B2
公开(公告)日:2013-07-02
申请号:US12969039
申请日:2010-12-15
申请人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
发明人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
CPC分类号: G01N33/6893 , G01N2333/4728 , G01N2333/52 , G01N2333/71 , G01N2333/8125 , G01N2800/347 , G01N2800/52 , G01N2800/56
摘要: Disclosed is use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
摘要翻译: 公开了使用尿液和血清生物标志物诊断糖尿病肾病,分期糖尿病肾病,监测糖尿病肾病进展和评估糖尿病肾病治疗效果。 这些生物标志物包括尿前体α-2-HS-糖蛋白,尿α-1抗胰蛋白酶,尿α-1酸糖蛋白,尿骨桥蛋白,血清骨桥蛋白,其片段及其组合。
-
公开(公告)号:US20100136579A1
公开(公告)日:2010-06-03
申请号:US12628758
申请日:2009-12-01
申请人: Tzu-Ling Tseng , Hung-Yi Li , Yen-Peng Li , Angelina Huai-Lo Lee , Yi-Chen Liu , Ping-Fu Cheng , Wei-Ya Lin , Hong-Zen Yeh
发明人: Tzu-Ling Tseng , Hung-Yi Li , Yen-Peng Li , Angelina Huai-Lo Lee , Yi-Chen Liu , Ping-Fu Cheng , Wei-Ya Lin , Hong-Zen Yeh
IPC分类号: G01N33/573 , C12Q1/52 , C12Q1/37
CPC分类号: G01N33/6893 , G01N33/487 , G01N33/49 , G01N33/50 , G01N33/5067 , G01N33/53 , G01N33/576 , G01N2333/70539 , G01N2333/96494 , G01N2333/9723 , G01N2800/085
摘要: Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.
摘要翻译: 鉴定尿激酶型纤溶酶原,基质金属蛋白酶9和&bgr.2-微球蛋白作为与肝纤维化相关的新型生物标志物及其在诊断肝纤维化中的用途。
-
公开(公告)号:US20100197033A1
公开(公告)日:2010-08-05
申请号:US12694575
申请日:2010-01-27
申请人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
发明人: Wei-Ya Lin , Mary Ya-Ping Yeh , Tzu-Ling Tseng , Ping-Fu Cheng , Tsai-Wei Hsu , Hung-Yi Li , Yi-Ting Chen , Yuh-Feng Ling , Jin-Shuen Chen , Yen-Peng Li
IPC分类号: G01N33/48
CPC分类号: G01N33/6893 , G01N2333/4728 , G01N2333/52 , G01N2333/71 , G01N2333/8125 , G01N2800/347 , G01N2800/52 , G01N2800/56
摘要: Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
摘要翻译: 使用尿液和血清生物标志物诊断糖尿病肾病,分期糖尿病肾病,监测糖尿病肾病进展,评估糖尿病肾病治疗效果。 这些生物标志物包括尿前体α-2-HS-糖蛋白,尿α-1抗胰蛋白酶,尿α-1酸糖蛋白,尿骨桥蛋白,血清骨桥蛋白,其片段及其组合。
-
-
-
-
-
-